Extract
Nintedanib, a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF), reduces annual forced vital capacity (FVC) decline in these patients by ∼50% with combined analysis of data from clinical trials showing a trend towards reduction in mortality [1–3]. Nintedanib prescription criteria for the treatment of IPF vary between countries and in 2016, the National Institute for Health and Care Excellence approved nintedanib in England and Wales for patients with an FVC between 50% and 80% predicted [4]. Prior to this approval, nintedanib was available through a manufacturer-funded programme with varying prescribing criteria. We investigated the safety and tolerability of nintedanib in UK clinical practice during this period in which FVC prescription criteria differed from those now available in routine practice.
Abstract
In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67
Footnotes
Conflict of interest: S.V. Fletcher reports receiving funding to attend conferences, speaker fees and fees for advisory boards from Roche and Boehringer Ingelheim.
Conflict of interest: M.G. Jones has nothing to disclose.
Conflict of interest: E.A. Renzoni reports receiving lecture fees from Boehringer, Roche and Takeda outside the submitted work.
Conflict of interest: H. Parfrey reports receiving personal fees for consultancy work from Boehringer Ingelheim and Roche, and nonfinancial support for conference attendance from Boehringer Ingelheim and Roche.
Conflict of interest: R.K. Hoyles reports receiving support for a specialist interstitial lung disease nurse (part time) for 1 year outside the submitted work.
Conflict of interest: K. Spinks reports receiving advisory board fees and conference sponsorship from Boehringer Ingelheim, and educational meeting sponsorship from Roche, outside the submitted work.
Conflict of interest: M. Kokosi has nothing to disclose.
Conflict of interest: A. Kwok has nothing to disclose.
Conflict of interest: C. Warburton has nothing to disclose.
Conflict of interest: V. Titmuss reports receiving personal fees for discussion on the new formulary of pirfenidone and its new patient information leaflet from the Roche Nurse Advisory Board outside the submitted work.
Conflict of interest: M. Thillai has received travel scholarships and consultancy fees from Boehringer Ingelheim and Roche.
Conflict of interest: N. Simler has nothing to disclose.
Conflict of interest: T.M. Maher reports receiving grant funding to his institution and personal fees for service on a clinical trial advisory board from GSK; personal fees from Boehringer Ingelheim, InterMune, Sanofi Aventis, AstraZeneca, Roche, Biogen Idec, Cipla, Prometic and Sanumed; research fees to his institution, personal fees and nonfinancial support from UCB; and holds stock options in Apellis, all outside the submitted work.
Conflict of interest: C.J. Brereton reports receiving support to attend a conference from Boehringer Ingelheim outside the submitted work.
Conflict of interest: F. Chua has nothing to disclose.
Conflict of interest: A.U. Wells reports receiving fees for consulting and speaking from Intermune/Roche, Boehringer Ingelheim and Bayer, fees for consulting from Gilead, outside the submitted work.
Conflict of interest: L. Richeldi reports grants and personal fees for service on an advisory board from InterMune, personal fees for service on an advisory board from Medimmune, Roche and FibroGen, personal fees for consulting activity from Biogen, Sanofi-Aventis, ImmuneWorks, Celgene and Nitton, a speaker fee from Shionogi, and personal fees for service on a steering committee from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: L.G. Spencer has received payments for advisory boards and travel support to attend respiratory conferences from both Boehringer Ingelheim and Roche, and speaker fees from Boehringer Ingelheim in the last 36 months.
- Received March 29, 2018.
- Accepted August 25, 2018.
- Copyright ©ERS 2018
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.